E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 1/12/2006 in the Prospect News Biotech Daily.

Chembio selected by Clinton AIDS initiative to provide rapid HIV tests

By E. Janene Geiss

Philadelphia, Jan. 12 - Chembio Diagnostics, Inc. has been selected by the Clinton Foundation HIV/AIDS Initiative, spearheaded by former President Bill Clinton, to make available rapid HIV tests that will be used to detect the infection easily and cost effectively.

The announcement was made Thursday at a press conference in which Clinton and members of the initiative's team discussed the importance of reaching out to those in need by ramping up the availability of rapid tests for AIDS while keeping the costs affordable, according to a company news release.

Clinton explained that Chembio and the three other chosen companies are helping to make this possible through their reasonable pricing and proficiency, officials said.

It was estimated that, to reach treatment targets, at least 200 million HIV tests will be necessary over the next four years, officials said.

"The missions of Chembio and the [Clinton Foundation HIV/AIDS Initiative] to help wipe out the scourge of AIDS worldwide are closely aligned. Thus we are extremely proud to be part of the Clinton HIV initiative, working with such a dedicated leader as President Clinton, his team, and our fellow companies in this critical initiative," Larry Siebert, president and chief executive officer of Chembio, said in the release

Those served by this initiative are members of the initiative's procurement consortium, which is currently comprised of 50 countries in Africa, Asia, Eastern Europe, Latin America and the Caribbean. The HIV-infected populations in these countries account for three-quarters of the global need for anti-retroviral treatment, officials said.

Chembio, based in Medford, N.Y., develops and manufactures rapid test products for various infectious diseases, including HIV, tuberculosis and Chagas disease.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.